<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Biogen Inc. were down 3.6% in premarket trading on Thursday after the company updated the label for its new Alzheimer’s disease treatment, Aduhelm. The Food and Drug Administration approved the label update, which now says that the therapy should be used in patients with “mild cognitive impairment or mild dementia stage of disease” because that is the group of people who were studied in the clinical trials.
...read full article on Market Watch
